Pfizer just penned a $6 billion licensing deal with China's 3SBio to develop and commercialize a cancer drug, SSGJ-707. The ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...

Guardant and Pfizer will use liquid biopsy tests in global oncology clinical trials ... testing capabilities in China through an existing partnership with Adicon Holdings. Feel unsure about ...

Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

and global Pfizer RWE leaders to explore the potential of Abu Dhabi’s Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to ...

Revolve Wealth Partners LLC lifted its holdings ... analysts have recently commented on the stock. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond infectious diseases.

Under the multi-year collaboration agreement, Guardant and Pfizer ... for their global clinical trials that include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

Yu Xuefeng, CEO of Chinese vaccine company CanSino Biologics, says the company remains on-track to breakeven in 2025, and remains committed to expanding into the global ... and 70 Pfizer's CEO ...